Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Topics

Hepatocellular carcinoma · Transarterial chemoembolization · Immune checkpoint inhibitor therapy · VEGF inhibition · Tyrosine kinase inhibitor · vascular endothelial growth factor (VEGF) · First-line treatment · Advanced hepatocellular carcinoma · target trial emulation · Inverse probability of treatment weighting · Overall survival · Progression-free survival · Objective response rate · RECIST 1.1 · Modified RECIST (mRECIST) · TACE-ICI-VEGF combination therapy · retrospective cohort study · Multicenter study · hazard ratio · Adverse events · combination immunotherapy · Locoregional therapy · Systemic therapy · tumor response · safety profile · Inverse probability of treatment weighting · First-line treatment · VEGF inhibition · causal inference methods · observational study design